MOH
- Marketing authorisation holder: OMEROS CORP
- Status: likely_approved
Yartemlea (NARSOPLIMAB) regulatory status in Israel.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
OMEROS CORP holds the Israeli marketing authorisation.